- Home
- MIRA vs PTN Comparison
MIRA vs PTN Comparison
Compare MIRA & PTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRA
- PTN
- Stock Information
- Founded
- MIRA 2020
- PTN 1986
- Country
- MIRA United States
- PTN United States
- Employees
- MIRA N/A
- PTN N/A
- Industry
- MIRA Biotechnology: Pharmaceutical Preparations
- PTN Biotechnology: Pharmaceutical Preparations
- Sector
- MIRA Health Care
- PTN Health Care
- Exchange
- MIRA Nasdaq
- PTN Nasdaq
- Market Cap
- MIRA 20.5M
- PTN 20.9M
- IPO Year
- MIRA 2023
- PTN 1993
- Fundamental
- Price
- MIRA $0.95
- PTN $0.54
- Analyst Decision
- MIRA Strong Buy
- PTN Strong Buy
- Analyst Count
- MIRA 2
- PTN 1
- Target Price
- MIRA $14.00
- PTN $7.00
- AVG Volume (30 Days)
- MIRA 360.9K
- PTN 904.9K
- Earning Date
- MIRA 05-12-2025
- PTN 05-14-2025
- Dividend Yield
- MIRA N/A
- PTN N/A
- EPS Growth
- MIRA N/A
- PTN N/A
- EPS
- MIRA N/A
- PTN N/A
- Revenue
- MIRA N/A
- PTN $350,000.00
- Revenue This Year
- MIRA N/A
- PTN N/A
- Revenue Next Year
- MIRA N/A
- PTN N/A
- P/E Ratio
- MIRA N/A
- PTN N/A
- Revenue Growth
- MIRA N/A
- PTN N/A
- 52 Week Low
- MIRA $0.51
- PTN $0.46
- 52 Week High
- MIRA $5.01
- PTN $2.88
- Technical
- Relative Strength Index (RSI)
- MIRA 38.16
- PTN 28.90
- Support Level
- MIRA $1.06
- PTN $0.68
- Resistance Level
- MIRA $1.29
- PTN $0.84
- Average True Range (ATR)
- MIRA 0.11
- PTN 0.08
- MACD
- MIRA -0.02
- PTN -0.02
- Stochastic Oscillator
- MIRA 4.74
- PTN 20.22
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
About PTN Palatin Technologies Inc.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.